
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Veralox Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
Veralox Expands Pipeline with Exclusive Option to Acquire Nudge Therapeutics
Details : Through the acquisition, Veralox expands its pipeline by including preclinical cyclic AMP-GMP (cGAS) inhibitor compounds.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 09, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Veralox Therapeutics
Deal Size : Undisclosed
Deal Type : Acquisition
